NCT06548178View on ClinicalTrials.gov

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

242

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2028

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

T-DXd

T-DXd (5.4 mg/kg Q3W on Day 1) ×6 cycles.

DRUG

THP

Docetaxel (75 mg/m2 Q3W on Day 1) concurrent with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg Q3W on Day 1) and pertuzumab (840 mg loading dose followed by 420 mg Q3W on Day 1) × 6 cycles.

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT06548178 - T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer | Biotech Hunter | Biotech Hunter